{"page":{"totalFilteredElements":80},"studies":[{"active":true,"description":"Einseitige Implantation des SPIRION Kehlkopfschrittmachers bei Patienten mit vorheriger permanenter Glottis-Erweiterung","eudractNumber":null,"id":8773,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":"NCT06007144","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-08-18T11:15:15+02:00","shortTitle":"(GLP) Voroperationen am Kehlkopf","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leuk&#228;mie und verwandten Vorl&#228;ufer-Neoplasien und der akuten Leuk&#228;mie unklarer Linienzugeh&#246;rigkeit: Das AMLSG Biology and Outcome (BIO)-Projekt</div>","eudractNumber":null,"id":953,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT01252485","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-08-01T09:31:52+02:00","shortTitle":"AMLSG BIO","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Zanubrutinib (Brukinsa&#174;) in Patients With Waldenstr&#246;m's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) - a Prospective Multicenter Observational Cohort Study","eudractNumber":null,"id":10642,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05326308","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-09T11:00:27+01:00","shortTitle":"ARIADNE","therapeutical":false,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"Real World Evalauation of efficacy and safety with Avelumab+Axitinib in patients with advanced Renal-Cell Carcinoma (RCC) in multiple EU countries","eudractNumber":null,"id":7080,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT04941768","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-22T08:18:43+02:00","shortTitle":"AVION","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Encorafenib Plus Binimetinib in Patients With Locally Advanced, \nUnresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, \nMultinational, Prospective, Longitudinal, Non-interventional Study in \nGermany, Austria and Switzerland","eudractNumber":null,"id":5940,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT04045691","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2019-10-31T08:21:58+01:00","shortTitle":"BERING MELANOMA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Epidemiologische Studie zur Bestimmung der Pr&#228;valenz von ctDNA-Positivit&#228;t bei Teilnehmern mit CRC im Stadium II (hohes Risiko) oder Stadium III nach einer Operation mit kurativer (R0) Absicht und anschlie&#223;ender adjuvanter Chemotherapie mit &#220;berwachung der ctDNA w&#228;hrend der klinischen Nachsorge","eudractNumber":null,"id":8552,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT04813627","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-20T08:23:42+02:00","shortTitle":"BNT000-001","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>PiR-HoP aimed at establishing a multi-site prospective clinical registry for two specific groups of prostate cancer patients, who present a particular clinical challenge:</div><div>&#61623; the oligometastatic prostate cancer</div><div>&#61623; the high risk prostate cancer in young patients</div>","eudractNumber":null,"id":11017,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-08-02T09:48:11+02:00","shortTitle":"BZKF- PiR-hoP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht interventionelle Langzeitstudie (NIS) zum klinischen Einsatz von Biotest IVIGs in verschiedenen Indikationen.&#160;","eudractNumber":null,"id":7451,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-09-01T11:57:57+02:00","shortTitle":"Biotest NIS-020 (IVIG)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive und Retrospektive Registerstudie der German Breast Group (GBG) Zur Diagnostik und Therapie des Mammakarzinoms in der Schwangerschaft mit jungen, nicht schwangeren Patientinnen (&lt;40Jahre) als Vergleichskohorte","eudractNumber":null,"id":7904,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT00196833","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-01-01T08:20:45+01:00","shortTitle":"Breast Cancer in Pregnancy (BCP)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>A non-interventional study for Kisqali (Ribociclib) in combination with an aromatase inhibitor in patients with HR+/HER2- stage II and III early breast cancer to evaluate</div><div>real-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN).</div>","eudractNumber":null,"id":10286,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06830720","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-02-26T08:44:55+01:00","shortTitle":"CAROLEEN","therapeutical":false,"therapyLines":[]}]}